Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

I multiple-dose HCV trial were presented that showed bavituximab was well tolerated and demonstrated encouraging signs of anti-viral activity.

Cotara(R) Brain Cancer Clinical Program

To help accelerate the ongoing Phase II trial of Cotara in patients with glioblastoma multiforme, one of the most deadly forms of brain cancer, Peregrine recently added two new sites to the study, for a total of seven clinical sites now actively screening and recruiting patients. In addition, Peregrine regained operational responsibility for the ongoing Cotara dosimetry and dose confirmation clinical study and is working closely with the participating academic medical centers to complete patient enrollment and dosing during 2008. Positive results from these two clinical trials are expected to pave the way for Phase III product registration trials for Cotara.

Mr. King concluded, "In 2008 we plan to conduct a number of mid-phase trials for our lead clinical programs, each of which has significant clinical and commercial potential. We have long maintained that positive Phase II clinical data would be the keys to building sustainable shareholder value in the company, and we are optimistic that Peregrine will be able to begin delivering on that promise in the upcoming year."

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional informatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 When a leading ... a request to design an industrial oven ... prescription medications being produced using a 3D-printing process, ... a robotic gantry, heat-saving windows, and internal actuators ... of 3D-printed pills to exact specifications. , To ...
(Date:5/29/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today that ... United Therapeutics, will provide an overview and update on the ... New York City . The ... on Thursday, June 4, 2015, at 11:00 AM Eastern Time, ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "Alzheimer Disease ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in management. With nearly 8 million sufferers ... markets of the world and anticipated increases ...
(Date:5/28/2015)... , May 27, 2015 Research ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
Breaking Biology Technology:New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an ... to be launched by,the Company into the China market. ... I tests in July 2006, which consists of tests,for ... tested in,Phases II & III. Aida is currently undergoing ...
... and DETROIT, Oct. 22 The Michigan Life,Science ... rapidly,stimulate new business for Michigan companies. (Photo: ... BioPharma Company, LLC and the Michigan Virtual,Medical Device ... exhibit during,the MichBio Expo convention in Lansing, Michigan. ...
... Highlight and ... of Advanced Practices by Leading, Interventionalists, Broadcast from Around the World. - Hear About ... Stent, Results. - See How Many of the Major Fixed Imaging and Stent Manufacturers ... are Embracing IVUS., ...
Cached Biology Technology:Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 2Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 3Virtual Life Science Companies Launch and Tour 2Virtual Life Science Companies Launch and Tour 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... contains stem cells with a surprising capacity for repair, ... journal Cell, published by Cell Press. The novel insight ... have clinical implications for the treatment of brain damage, ... mice whose brains were severely damaged by loss of ...
... they have been exposed to biological or chemical weapons could ... who are helping to develop a tiny diagnostic device that ... of a tiny pump, researchers affiliated with MIT's Institute for ... existing miniature "lab on a chip" fully portable, so the ...
... heat-loving archaeon capable of fixing nitrogen at a surprisingly ... Earth’s earliest lineages of organisms capable of nitrogen fixation, ... and animals rely on to fix nitrogen. , ... of Science supports the notion that the gene needed ...
Cached Biology News:Neural stem cells lend the brain a surprising capacity for self-repair 2MIT designs portable 'lab on a chip' 2MIT designs portable 'lab on a chip' 3Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
... ZMD.440. Immunogen: Synthetic peptide derived from ... (platelet derived growth factor D iris-expressed growth ... differs from mouse and rat by one ... the ~50 kDa human mouse and rat ...
...
...
...
Biology Products: